Nous utilisons des cookies
En cliquant sur « Accepter », vous acceptez que des cookies soient stockés sur votre appareil afin d'améliorer la navigation sur le site, d'analyser l'utilisation du site et de nous aider dans nos efforts de marketing. Consultez nos mentions légales pour plus d'informations.
Accueil
Actualités & Perspectives

Launch of Enosium Life Science

27/5/24

Press release

Enosium Life Science, a new unique integrated scientific services group for the life science industries in Europe

Paris, France, 5 March 2024 – The creation of Enosium Life Science marks the first step in founder Dr Antoine Amer’s five-year plan to become the leading scientific services provider, addressing the current challenges across Europe’s medical and pharmaceutical innovation ecosystem. Backed by major French private investment firm Otium Capital, Enosium Life Science will implement a targeted acquisition strategy to build a multi-specialist group on a European scale, supporting the entire healthcare product value chain, from clinical development to commercialisation

Enosium Life Science was founded by Antoine Amer, a medical doctor with an MBA fromESCP and Harvard Business School. With over 20 years of pharmaceutical leadership experience, both on a European and international scale, Dr. Amer brings in-depth knowledge of the healthcare ecosystem, particularly when it comes to the commercial development and launch of medical innovations. With the financial backing of Otium Capital, a major investor in high-potential businesses, Enosium Life Science has both the ambition and the resources to become Europe's leading provider of scientific services for the healthcare industry within the next five years.

A Multi-Specialist European Group Dedicated to Life Sciences

Enosium Life Science will have a unique offer, integrating complementary services to meet the critical needs of the pharmaceutical, biotechnology and medtech industries. The group will operate under an innovative model, combining extensive local knowledge, scientific expertise and entrepreneurial agility with the high standards and synergies of an international group.

An acquisition strategy focused on five key areas of expertise

Bolstered by local expertise and international reach, Enosium Life Science's strategy is focused on selected and targeted acquisitions in five key areas: clinical research (or 'CRO'), regulatory affairs, market access and health economics, medical affairs and marketing. By creating a community of best-in-class European experts, Enosium Life Science will be able to offer tailored advisory services, along with innovative, cutting-edge solutions, in order to meet the challenges faced by pharmaceutical firms throughout the entire healthcare product lifecycle.

Antoine Amer, Founder and CEO of Enosium Life Science:

“Healthcare industries arefacing increasing environmental complexity, high development and marketing costs, as well asgrowing uncertainties associated with the introduction of innovations across Europe. Ourvision is to bring together leading European expertise, to offer a unique, comprehensive rangeof scientific services to help them better meet these challenges, giving European patients fasterand broader access to medical innovations.”

François Durvye, Otium Capital CEO:

“Investing in Enosium Life Science demonstratesOtium Capital’s commitment to supporting innovation and excellence in the field of lifesciences. By backing Enosium Life Science, led by Antoine Amer, we are making a strategicinvestment that reflects our desire to create a lasting positive impact within the healthcaresector, tackling the major challenges facing medical innovation, and improving patients’ healthand quality of life.”

Basile Paul-Petit, Buy&Build Partner at Otium Capital:

“We are delighted to supportAntoine Amer in the creation of Enosium Life Science, and to help the group achieve its ambition to become Europe’s leading player in life sciences within the next five years. Following the great successes of Otium Leisure within the leisure industry, Novavet in veterinary clinics, Otelium in hospitality and the launch a few months back of Alfeor within the nuclear sector, Otium Capital continues to deploy its buy-and-build strategy across various strategic sectors, in line with its long-term vision.”

About Enosium Life Science

Enosium Life Science is an integrated scientific services group for the European life science market. Providing comprehensive expertise ranging from strategy to execution, as well as highly specialized services from clinical development through to commercialisation (clinical research, regulatory affairs, market access, medical affairs, marketing), Enosium Life Science is committed to becoming the partner-of-choice for the healthcare industries, and to address the critical local challenges facing pharma, biotech and medtech companies. For further information: www.enosium.com

About Otium Capital

Otium Capital is a major player in private investment in France with €1.5 billion in assets under management. Serving as the Family Office for French entrepreneur and founder of Smartbox Pierre-Edouard Stérin, Otium Capital invests across various domains. With significant experience in healthcare (Owkin, Hapni, Okomera, etc.) and expertise in buy-and-build strategies (Otium Leisure, Novavet, Otelium, Alfeor), Otium Capital is a key player in fostering innovation and growth. For further information: www.otiumcapital.com